Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

OTLK 10.17.2024

Full Press ReleaseSEC FilingsOur OTLK Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
  • 01.16.2025 - Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
  • 01.08.2025 - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Recent Filings

  • 01.22.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 8-K Current report
PDF Version

Access the CEO Connect segment here

ISELIN, N.J.,Oct. 17, 2024(GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in theEuropean Unionand theUnited Kingdomearlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced thatRussell Trenary, President and CEO ofOutlook Therapeuticsparticipated in aVirtual Investor CEO Connectsegment.

As part of this segment,Mr. Trenaryprovided an overview of the Company’s recent accomplishments and highlighted near-term value driving milestones as the Company works toward the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD. The Virtual Investor CEO Connect featuringOutlook Therapeuticsis now availablehere.

AboutOutlook Therapeutics, Inc.

Outlook Therapeuticsis a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVATM (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVATM (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receiveEuropean Commissionand MHRA Marketing Authorization for the treatment of wet AMD.Outlook Therapeuticsis working to initiate its commercial launch of LYTENAVATM (bevacizumab gamma) in the EU and theUKas a treatment for wet AMD, expected in the first half of calendar 2025. Inthe United States, ONS-5010/LYTENAVATM is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA inthe United States. If approved inthe United States, ONS-5010/LYTENAVATM, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:Jenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775OTLK@jtcir.com

Primary Logo

Source: Outlook Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com